ATE79270T1 - Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma. - Google Patents

Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma.

Info

Publication number
ATE79270T1
ATE79270T1 AT90104423T AT90104423T ATE79270T1 AT E79270 T1 ATE79270 T1 AT E79270T1 AT 90104423 T AT90104423 T AT 90104423T AT 90104423 T AT90104423 T AT 90104423T AT E79270 T1 ATE79270 T1 AT E79270T1
Authority
AT
Austria
Prior art keywords
molecules
asthma
treatment
intercellular
adhaesion
Prior art date
Application number
AT90104423T
Other languages
German (de)
English (en)
Inventor
Craig D Wegner
Robert H Gundel
Robert Rothlein
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE79270T1 publication Critical patent/ATE79270T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70525ICAM molecules, e.g. CD50, CD54, CD102
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • C07K14/70553Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT90104423T 1989-03-09 1990-03-08 Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma. ATE79270T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32123789A 1989-03-09 1989-03-09
US32101889A 1989-03-09 1989-03-09
US32123989A 1989-03-09 1989-03-09
US32448189A 1989-03-16 1989-03-16
US40140989A 1989-09-01 1989-09-01

Publications (1)

Publication Number Publication Date
ATE79270T1 true ATE79270T1 (de) 1992-08-15

Family

ID=27541038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90104423T ATE79270T1 (de) 1989-03-09 1990-03-08 Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma.

Country Status (13)

Country Link
EP (1) EP0387701B1 (forum.php)
JP (1) JP3119483B2 (forum.php)
KR (1) KR0177519B1 (forum.php)
AT (1) ATE79270T1 (forum.php)
AU (1) AU638450B2 (forum.php)
CA (1) CA2047721C (forum.php)
DE (1) DE69000248T2 (forum.php)
DK (1) DK0387701T3 (forum.php)
ES (1) ES2035668T3 (forum.php)
GR (1) GR3006073T3 (forum.php)
HU (1) HU216313B (forum.php)
NZ (1) NZ232868A (forum.php)
WO (1) WO1990010453A1 (forum.php)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
ATE186552T1 (de) 1988-09-01 1999-11-15 Bayer Ag Menschliches rhinovirusrezeptorprotein, das die virusinfektionsanfälligkeit hemmt
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
ATE184049T1 (de) * 1990-07-20 1999-09-15 Bayer Ag Multimere formen des menschlichen rhinovirus- rezeptorproteins
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
CA2092801A1 (en) * 1990-10-03 1992-04-04 Randall Barton Method for treating inflammation using anti-idiotypic antibodies
CA2056143A1 (en) * 1990-11-28 1992-05-29 Michael S. Diamond The mac-1 binding site of icam-1
DK0507187T3 (da) * 1991-04-03 1997-04-07 Boehringer Ingelheim Pharma Fremgangsmåde til hæmning af pulmonær oxygentoksicitet
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
KR100252621B1 (ko) * 1991-07-31 2000-09-01 데이비드 이. 프랭크하우저 내피성-백혈구 부착 분자-1 및 그에 대한 항체의 천식치료에 있어서의 용도
CA2120500A1 (en) * 1991-10-01 1993-04-15 Mitsuaki Isobe Preventing allograft rejection with antibodies to adhesion molecules
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
JPH06510208A (ja) * 1992-06-22 1994-11-17 マイルス・インコーポレーテツド 多量体形態のヒトライノウイルスレセプタ蛋白質
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
CA2898314A1 (en) 2001-07-19 2003-07-31 Perian Therapeutics, Inc. Multimeric proteins and methods of making and using same
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854536T2 (de) * 1987-05-04 1996-03-07 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor

Also Published As

Publication number Publication date
HU902883D0 (en) 1991-12-30
HUT65843A (en) 1994-07-28
EP0387701A1 (en) 1990-09-19
CA2047721A1 (en) 1990-09-10
KR0177519B1 (ko) 1999-03-20
AU5349990A (en) 1990-10-09
DK0387701T3 (da) 1992-12-07
KR920700667A (ko) 1992-08-10
HU216313B (hu) 1999-06-28
JPH04504127A (ja) 1992-07-23
JP3119483B2 (ja) 2000-12-18
DE69000248D1 (de) 1992-09-17
AU638450B2 (en) 1993-07-01
DE69000248T2 (de) 1993-01-07
ES2035668T3 (es) 1993-04-16
NZ232868A (en) 1995-05-26
EP0387701B1 (en) 1992-08-12
CA2047721C (en) 2004-01-06
WO1990010453A1 (en) 1990-09-20
GR3006073T3 (forum.php) 1993-06-21

Similar Documents

Publication Publication Date Title
ATE79270T1 (de) Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma.
DE69130445D1 (de) Die Mac-1-Bindungsstelle von ICAM-1
DE59000652D1 (de) Verwendung von umsetzungsprodukten von alkenylspirobislactonen und aminen als paraffindispergatoren.
ATE73045T1 (de) Verfahren zur herstellung von holzspanplatten u.dgl. und entsprechende doppelbandpressen.
ATE291011T1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
DE69829763D1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE69523654D1 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
DE3876688D1 (de) Thixothrope anstrichmittelzusammensetzung und gegenstaende damit.
DE69432429D1 (de) Palladiumkomplexe und verfahren zu ihrer verwendung in der behandlung von tumoren und psoriasis
DE69833297D1 (de) Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS)
DE69716896D1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE3483989D1 (de) Cumarinderivate, diese enthaltende pharmazeutische zubereitungen und ihre verwendung bei der behandlung von krebs.
DE59009684D1 (de) Mittel zur Verbesserung der Wiederfindung von Annexinen.
FI981642A7 (fi) Solujen välisiä kiinnikemolekyylejä ja niiden sitoutumisligandeja
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
EP0757697A4 (en) Use of agents which block intercellular adhesion molecule/receptor interaction in the treatment of respiratory viral infection
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
DE69004301D1 (de) Mischung zur Behandlung der von exokrinen Insuffizienz der Bauchspeicheldrüse und die Verwendung der genannten Mischung.
DE69629931D1 (de) 1-(hetero)aryl-4-(kondensiertes thiazol-2-ylalkyl)-piperazin derivate, deren herstellung und deren verwendung in der behandlung von 5-ht1a-rezeptor vermittelten krankheiten
ATE230267T1 (de) Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
DE68900867D1 (de) 1,5-benzothiazepinderivate, ihre herstellung und ihre verwendung in der behandlung von kardiovasculaeren stoerungen.
DE3766258D1 (de) Spiegelndes produkt von goldener faerbung und verfahren zu dessen herstellung.
DE69717508D1 (de) Amphiphile perfluoroalkyl-modifizierte polydiene und ihre verwendung in der bearbeitung von leder

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time